Myelodysplastic Syndromes Clinical Trials in Paris
11 recruitingParis, France
Showing 1–11 of 11 trials
Recruiting
Phase 1Phase 2
A Study of BGB-11417 in Participants With Myeloid Malignancies
Acute Myeloid LeukemiaMyelodysplastic SyndromesMyelodysplastic/Myeloproliferative Neoplasm
BeiGene260 enrolled46 locationsNCT04771130
Recruiting
Phase 2
A Study of Momelotinib in Participants With Low-risk Myelodysplastic Syndrome
Myelodysplastic Syndromes
GlaxoSmithKline80 enrolled39 locationsNCT06847867
Recruiting
Phase 3
Ivosidenib (IVO) Monotherapy and Azacitidine (AZA) Monotherapy in Patients With Hypomethylating Agent (HMA) Naive Myelodysplastic Syndromes (MDS) With an IDH1 Mutation
Myelodysplastic Syndromes (MDS)Hypomethylating Agent (HMA) Naive Myelodysplastic Syndromes (MDS)
Institut de Recherches Internationales Servier48 enrolled62 locationsNCT06465953
Recruiting
Phase 3
ELEMENT-MDS: A Study to Compare the Efficacy and Safety of Luspatercept in Participants With Myelodysplastic Syndrome (MDS) and Anemia Not Receiving Blood Transfusions
Myelodysplastic Syndromes
Bristol-Myers Squibb360 enrolled169 locationsNCT05949684
Recruiting
Phase 1Phase 2
A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
Multiple MyelomaMyelodysplastic SyndromesLeukemia, Myeloid, Acute+1 more
Sumitomo Pharma America, Inc.606 enrolled104 locationsNCT04988555
Recruiting
Phase 3
A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions
Myelodysplastic Syndromes
Takeda225 enrolled155 locationsNCT06499285
Recruiting
Phase 1Phase 2
Study Evaluating Combination of Luspatercept in LR-MDS Without RS Having Failed or Being Ineligible to ESA
MDSMyelodysplastic Syndromes
Groupe Francophone des Myelodysplasies150 enrolled40 locationsNCT05181735
Recruiting
Phase 2
A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS)
Myelodysplastic SyndromesCytopenia
Takeda160 enrolled47 locationsNCT04419649
Recruiting
Phase 3
A Study to Evaluate Long-term Safety in Participants Who Have Participated in Other Luspatercept (ACE-536) Clinical Trials
Myelodysplastic Syndromes (MDS)
Celgene665 enrolled143 locationsNCT04064060
Recruiting
Phase 1
Study of REM-422 in Patients With AML or Higher Risk MDS
Acute Myeloid LeukemiaMyelodysplastic SyndromesHigher Risk Myelodysplastic Syndromes
Remix Therapeutics100 enrolled9 locationsNCT06297941
Recruiting
Phase 2
Faecal Microbiota Transplantation After Allogeneic Stem Cell Transplantation
Chronic Lymphocytic LeukemiaHodgkin LymphomaMyeloma+4 more
University Hospital, Clermont-Ferrand150 enrolled20 locationsNCT04935684